Progyny (NASDAQ:PGNY) CEO Pete Anevski said the company expects member engagement and utilization to rebound following a more pronounced summer seasonal slowdown, while early renewal and new-client commitments have increased management’s confidence in its outlook for the remainder of the year. Spea

Progyny’s second quarter results were met with a negative market reaction, despite the company delivering revenue and non-GAAP profit above Wall Street expectations. CEO Peter Anevski attributed the quarter’s growth to continued demand from employers for family building and women’s health solutions, emphasizing strong retention and early client commitments. Management noted that higher engagement levels and operational efficiencies contributed to margin expansion, while a more pronounced summer

Record revenue and gross profit as client count climbs to 604 and member base expands.

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Shares of fertility benefits company Progyny (NASDAQ:PGNY) fell 4.5% in the afternoon session after the company issued a weak forecast, overshadowing second-quarter results that beat expectations.

Progyny stock has delivered a 38.8% decline over the past five years, even though the valuation checks currently suggest the shares may be pricing in cautious expectations. Recent gains over the last year now sit alongside a high value score and a recent pullback, which raises questions about how the market is weighing Progyny's long term prospects against its current valuation. Over the past five years, Progyny has declined 38.8%. This shows that long term holders have faced a material...

IVZ, HUBS, HNGE and PGNY make the cut as the top liquid stocks, each boasting strong liquidity, growth attributes and operational efficiency.

Fertility benefits company Progyny (NASDAQ:PGNY) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 5.3% year on year to $350.5 million. On the other hand, next quarter’s revenue guidance of $340 million was less impressive, coming in 3% below analysts’ estimates. Its non-GAAP profit of $0.55 per share was 6.2% above analysts’ consensus estimates.

Progyny stock initially plummeted this morning but has steadily marched back toward even.

Moby summary of Progyny, Inc.'s Q2 2026 earnings call

Progyny (NASDAQ:PGNY) reported record quarterly revenue, gross profit and adjusted EBITDA for the second quarter of 2026, while management said early sales commitments and client-retention activity have positioned the company favorably for the 2027 selling season. Chief Executive Officer Pete Anevs

Progyny Inc (PGNY) reports strong Q2 2026 results with record quarterly revenue and adjusted EBITDA, while navigating summer seasonality and investing in future growth initiatives.

Although the revenue and EPS for Progyny (PGNY) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Progyny (PGNY) delivered earnings and revenue surprises of +7.84% and +0.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Fertility benefits company Progyny (NASDAQ:PGNY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 5.3% year on year to $350.5 million. On the other hand, next quarter’s revenue guidance of $340 million was less impressive, coming in 3% below analysts’ estimates. Its non-GAAP profit of $0.55 per share was 6.2% above analysts’ consensus estimates.

Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Disposition reduced her direct holdings by 5% through a combination of Rule 10b5-1 plan sales and tax-withholding shares, leaving her with a $2.26 million stake.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Progyny stock has climbed strongly in the near term and reached a fresh 52 week high, yet there is a clear split in what the valuation checks say, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to sizable upside while earnings based multiples suggest the shares already trade at a premium. Over 5 years, Progyny has delivered a decline of 43.1%, which means long term holders have not yet shared in the recent momentum. Upgraded analyst views and a stronger earnings outlook...

Earlier this week, several Wall Street firms issued upbeat research on Progyny, highlighting stronger June activity and signaling increased confidence in its upcoming earnings and guidance. This wave of positive analyst commentary underscores how closely investors are watching Progyny’s operating trends as a gauge of employer demand for fertility and family-building benefits. Next, we’ll examine how rising analyst optimism about June transaction trends could influence Progyny’s existing...

Check out the companies making headlines yesterday:

Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

Shares of fertility benefits company Progyny (NASDAQ:PGNY) jumped 3.5% in the afternoon session after KeyBanc raised its price target on the stock to $35 from $30, citing expectations of a strong earnings report and increased future guidance.